hit turbul aesthet
chang fve
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim oct
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
thank shift manag abl focu
structur competit advantag improv balanc sheet
judici step differ market even
vagari product cycl control roughli
 digit mammographi market lead way first
mammographi adopt slow still
opportun growth smaller hospit oversea
importantli clinic data still give edg
pricey gen-prob acquisit also hold top
posit host diagnost test focus women health
run sole proprietari instrument think
done good job capit prolifer low-
midvolum lab panther equip gain
traction expand recur revenu base
howev face secular competit hurdl
recommend cervic screen interv lengthen
reduc pap smear volum forc preserv
market share hpv price also fallen
dramat seek maintain share addit
heavy-weight siemen compet
mammographi market could challeng given ge
entrench select hospit abil bundl extens
menu capit equip
materi think abl navig
pressur center medicar medicaid servic
establish reimburs mammographi appear
lucr firm custom base help
adopt believ first-mov advantag
mammographi wide instal base strong trial valid
provid firm foot market recent addit
cynosur provid entre aesthet market less
reliant reimburs broaden portfolio
translat even growth along line
larger med-tech firm enjoy
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
manufactur proprietari product healthcar need
women compani oper four segment diagnost sale
breast health surgic skelet health
compani tradit focus breast health recent acquisit
gen-prob put much greater emphasi commerci diagnost
unit state account largest portion firm revenu
follow europ asia headquart
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
hit turbul aesthet
chang fve
post fiscal fourth-quart result
whole match estim fair valu
unchang hamper new market complic
medic aesthet segment saw fourth-quart
revenu grow constant currenc breast
health segment exceed project off-set
lower-than-expect gynecolog surgeri growth
likewis year outpac expect
off-set lower-than-expect spend
nonetheless saw littl materi chang longer-
term project narrow-moat compani
medic aesthet took chin declin
constant currenc fuel even steeper drop
bodi women health product line reflect
compani decis halt market monalisa touch
vagin rejuven follow food drug
administr warn letter summer letter
aim rang compani market
variou laser product stimul gener
collagen vagina therebi reliev
symptom associ hormon chang
post-menopaus women holog product base
laser technolog that approv aesthet
use includ reduc appear acn scar
howev off-label use vulvular region
steadili grow among practition aid market
manufactur wake report burn
complic vagin rejuven fda
taken aggress stanc demand clinic
support safeti efficaci procedur
end expect near-term drag aesthet
growth head fiscal impact
materi move valuat mainli bodi
women health categori within aesthet
segment account roughli total revenu
asid difficulti aesthet pleas
see solid growth breast health also like
recent tuck-in acquisit faxitron bioptic focal
therapeut add suit breast health
product compani doesnt necessarili enjoy scale
across multipl categori make smart
decis bulk product portfolio certain area
increas footprint offer rang
small tag implant breast design
lumpectomi took placedovetail nice firm
establish strength mammographi though type
acquisit rel small like make
strateg sens financi risk minim
hold steadi fair valu estim per
share follow addit cynosur divestitur
blood screen busi
holog abil integr cynosur maintain
gradual growth digit mammographi upgrad
cycl launch new diagnost test key
factor valuat continu think firm
well posit roll-out panther instrument
widen stream recur test revenu
also believ entri viral-load test
boost appeal assay menu aid stabil
hpv test market intern side
anticip near-term expans europ slow
entri emerg market play greater role
gain surgic skelet health taken togeth along
addit cynosur project compound-annual-growth-rate
explicit forecast period
believ price pressur persist across
product forecast gross margin increas
increment firm increas recur
revenu higher-margin test servic expans
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
recent establish public reimburs acceler
placement faster clip bull-cas fair
valu estim per share reflect compound
annual growth rate total revenu billion
fiscal
bear case competit price pressur across
busi segment hinder growth particularli
diagnost assum slowdown europ emerg
market anem perform medic aesthet
pressur rival allergan stringent
requir approv regulatori agenc
bear-cas fair valu estim per share reflect
compound annual growth total revenu
billion fiscal
believ dug narrow econom moat base
switch cost intellectu properti
surround breast health diagnost platform
pioneer first fda-approv mammographi
platform continu expand instal
base unit mammographi equip
typic big-ticket purchas hospit
radiolog clinic price tag per digit
unit per instal time
retrain system reorgan work flow mean
custom littl incent switch platform
furthermor consider less expens
holog custom upgrad equip rather
switch compet system sizabl instal
base firm also reap benefit five-year servic
contract annual cost purchas
price option instal base
fall contract
addit lengthi fda approv process
sophist technolog tall barrier deter
new market entrant though gener electr
instal base mammographi equip
new salesforc medic aesthet becom
product midterm
believ firm sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
firm abil maintain instal base
diagnost instrument expand test
menu well quickli medic aesthet
segment return market-r growth
bull-cas scenario assum
liquid-bas pap smear edg becton dickinson
market share volum reset market
stabil firm maintain healthi pace panther
instal could also captur greater share test
breast tomosynthesi gain better traction proven
efficaci cost-effect intern
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
siemen receiv fda approv system
add new level competit could appli
price pressur think grow bodi clinic data
geniu system help establish superior
mind clinician two year
new competit yet seen soft
averag sell price
acquir gen-prob diagnost
divis also leverag high switch cost
surround proprietari instrument test
run ad thinprep lead share
liquid-bas pap market acquisit dramat
hpv
chlamydia gonorrhea trichomona blood screen
lab commit firm autom equip
streamlin oper run compani test
consolid workflow fewer platform addit
time requir train lab technician adjust work flow
steep switch cost built around instrument
price tag built per-reag cost
addit cynosur provid sizabl
footprint aesthet market anticip holog
could bolster moat intellectu properti
surround cynosur variou laser may
opportun build brand segment
direct-to-consum commun allergan
botox unfortun investor need exercis
patienc work rebuild commerci
organ support medic aesthet busi
sinc acquisit announc steadi stream
entir salesforc ground
think holog remain segment surgic
skelet health moat firm hysteroscop
surgic product myosur led pocket success
strong cash flow howev lower-cost altern
put pressur novasur product advers
macroeconom condit result mix skelet
result nevertheless believ breast health
diagnost segment
believ moat trend stabl within breast
health competit ramp ge
siemen receiv regulatori approv rival
enjoy strong brand name access greater resourc
technolog innov nevertheless uptak
platform remain solid size
compani digit instal base give us confid
maintain momentum upgrad despit new
entrant market remain competit
need maintain technolog edg equip
upgrad new product introduct appeal
within diagnost consider headwind pap
smear market seem eas diagnost oem
adjust longer recommend test interv
push annual pap smear closer everi three five
year women need continu
expand menu test appeal commerci
lab enhanc front-end autom capabl
instrument
overal feel firm well posit
front firm enter viral-load test hiv hep
 area billion market allianc quest could
also open menu expans opportun firm
co-develop promot new diagnost solut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first market fda-approv
mammographi platform unit state give
consider head start gener electr
siemen
control lion share liquid-
base pap market gen-prob acquisit
catapult firm number-on posit
test chlamydia gonorrhea blood screen
ogovern reimburs mammographi
appear lucr custom base
acceler system placement
owith mammographi screen guidelin flux
potenti drop-off mammogram volum could hurt
product portfolio vari wide see
littl opportun effici use salesforc
call differ specialist
odespit full pipelin best effort high
degre clinic regulatori risk surround
product regulatori path approv
expens time-consum fruitless process
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
took consider leverag billion
acquisit gen-prob deleverag
ensu year avoid pile debt
purchas cynosur decemb owe
billion debt held million cash
hire former stryker ceo stephen macmillan
lead firm note prefer oper
firm substanti less leverag
balanc sheet held begin tenur
net debt/ebitda macmillan
balanc sheet typic held cash debt holog
set exceed goal time net debt/ebitda
end fiscal
believ sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
rate sale influenc capit spend
pattern hospit clinic could advers
affect prolong econom downturn effect
macroeconom downturn could exacerb
consum forgo cosmet laser treatment
interest tighten financi belt diagnost
market particip
also
competit firm sale could suffer screen
guidelin lengthen becom lenient furthermor
signific exposur regulatori risk
particularli within secur reimburs fda
approv new product introduct also
approxim sale come intern
market currenc headwind could neg impact
top- bottom-lin perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
american fund growth fund amer
capit research manag compani
share
fund
share
fund
award holog standard mark stewardship
stephen macmillan step ceo late
macmillan formerli serv ceo
corpor hold
year oper experi healthcar
industri overal think macmillan well suit
job follow effect tenur execut
number success direct make sound
acquisit experi benefit
oper strategi macmillan also track record
gener free cash flow manag debt holog
benefit firm deleverag balanc
sheet follow gen-prob acquisit put holog
favor posit make acquisit broaden
firm footprint
primari complaint holog acquisit
come hefti price follow substanti goodwil
write-off rack signific record
substanti write-off last nine year
recent impair million cynosur goodwil
revalu goodwil led billion
impair charg relat third wave
gen-prob even earlier billion
relat cytyc acquisit entir string
impair reflect current manag
team recogn cumul impact
independ decis differ manag
team cost sharehold point rather see
buy back share embark anoth larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intern growth boost chang
gener consist
expect leav fair valu estim
unchang consid time requir rebuild
aesthet salesforc continu hold temper
expect busi dont anticip
notic improv progress field
forc move along faster expect could see
improv pull forward fourth quarter thank
season nonetheless werent surpris
aesthet segment declin constant currenc
year year
hand reorgan new leadership
intern divis deliv impress
result growth constant currenc fuel
breast imag breast solut even
intern expect intern strength
sustain especi consid merit holog
diagnost technolog firm previous
devot rel littl attent intern expans
moreov
reorgan european oper instruct
ceo stephen macmillan divis
presid kevin thornal involv
thornal handiwork holog emea divis evid
strong result recent quarter thornal
lead rebuild effort legaci cynosur
confid matter time sale
organ staf train make call
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
